GAS／CCK-2R及其拮抗剂在胰腺癌治疗中的作用  

GAS/CCK-2R and function of its antagonists in treatment of the pancreatic cancer

作　　者：陈卫波[1] 吴俊华[1] 江春平[2] 

机构地区：[1]南京大学医学院,南京210093 [2]南京大学医学院附属鼓楼医院肝胆外科,南京210093

出　　处：《国际外科学杂志》2010年第9期609-612,共4页International Journal of Surgery

基　　金：基金编号：南京市卫生局重点基金资助项目（No.ZKX08025）

摘　　要：近年来发现胃泌素/胆囊收缩素-2受体（gastrin/cholecystokinin-2 receptors,GAS/CCK-2R）与胰腺癌的发生、发展有密切关系.它在人体内广泛分布,但不存在于正常胰腺外分泌部.CCK-2R在胰腺癌组织中出现异常表达,该表达引起了胰腺外分泌部蛋白的异常表达和激活,导致腺泡细胞形态学和表型的变化,并使胰腺对致癌物质的敏感性增加.一些GAS/CCK-2R拮抗剂可用于胰腺癌的早期和晚期治疗.Studies in recent years revel that there is a close relationship between gastrin/cholecystokinin-2 receptors （GAS/CCK-2R） and pancreatic cancer. CCK-2R is widely distributed in human body, but not in normal exocrine pancreas. However, CCK-2R is abnormally expressed in pancreatic carcinoma. The abnormal expression of CCK-2R in pancreatic tissues leads to the abnormal protein expression and activation, changes in acinar cells＇ morphology and phenotype and an increase in the sensitivity to carcinogenic substances. And some GAS/CCK-2R antagonists can be used for the early and late treatment of pancreatic cancer.

关 键 词：GAS/CCK-2R 胰腺癌 拮抗剂 

分 类 号：R735.9[医药卫生—肿瘤]